+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Unresectable Hepatocellular Carcinoma Market by Therapy Type, Mechanism Of Action, Line Of Therapy, Formulation, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Unresectable Hepatocellular Carcinoma Market by Therapy Type, Mechanism Of Action, Line Of Therapy, Formulation, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Unresectable Hepatocellular Carcinoma Market by Therapy Type, Mechanism Of Action, Line Of Therapy, Formulation, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715740
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior industry leaders face complex therapeutic and commercial decisions in the dynamic unresectable hepatocellular carcinoma market, where clinical unmet needs, evolving care pathways, and external economic forces continually reshape opportunity and challenge.

Market Snapshot: Unresectable Hepatocellular Carcinoma Market Overview

The unresectable hepatocellular carcinoma market experienced a notable increase in overall market size from USD 1.90 billion in 2024 to USD 2.16 billion in 2025 and is projected to maintain double-digit growth at a CAGR of 13.47%, reaching USD 4.05 billion by 2030. This momentum is driven by the emergence of next-generation therapeutics, ongoing regulatory evolution, and rising global demand for effective systemic strategies in advanced-stage disease.

Scope & Segmentation

This report provides an in-depth exploration of the unresectable hepatocellular carcinoma market, spanning major segments, technologies, and regional variations:

  • Therapy Type: Combination therapy, locoregional therapy, supportive care, and systemic therapy approaches are profiled, highlighting adoption dynamics and the role of integrated regimens.
  • Mechanism of Action: Immune checkpoint inhibitors (including CTLA-4, PD-1, PD-L1 inhibitors), mTOR inhibitors, multi kinase and selective kinase inhibitors, along with other targeted classes.
  • Line of Therapy: Coverage includes first-line, second-line, and third-line treatments, with emphasis on sequencing and therapeutic selection.
  • Formulation: Trends in oral and injectable delivery formats are assessed in alignment with provider and patient preferences.
  • Distribution Channel: Analysis encompasses hospital pharmacies, online pharmacies, and retail pharmacies, considering market access and dispensing environments.
  • End User: Home care settings, hospitals, and specialty clinics as principal end-user segments, reflecting clinical infrastructure impact on therapy uptake.
  • Regional Coverage: Americas (notably United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, Saudi Arabia, South Africa, among others), and Asia-Pacific (featuring China, India, Japan, Australia, and Southeast Asian growth markets).
  • Leading Companies: F. Hoffmann-La Roche Ltd, Genentech, Inc., Eisai Co., Ltd., Bayer AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Exelixis, Inc., and Eli Lilly and Company are profiled for their innovation, clinical leadership, and competitive strategy.

Key Takeaways

  • Combination therapies, especially those integrating immune checkpoint and kinase inhibitors, are driving a shift away from single-modality approaches and offer enhanced clinical benefit when aligned with appropriate patient profiles.
  • Systemic therapy adoption is accelerating across regions through heightened regulatory flexibility, expedited review timelines, and increased real-world evidence collection to support reimbursement and access.
  • Supply chain vulnerabilities, particularly those exposed by recent policy changes in major pharmaceutical markets, are influencing manufacturer investment in localized production and dual sourcing strategies.
  • Regional distinctions in clinical infrastructure, payer involvement, and patient demographics remain critical in the design of go-to-market strategies, especially for companies targeting emerging markets and high-burden geographies.
  • Biopharmaceutical innovators are leveraging strategic acquisitions and collaborations to expand precision medicine capabilities and enhance asset pipelines, responding to the need for personalized therapy and rapid trial activation.

Tariff Impact on the Unresectable Hepatocellular Carcinoma Market

Recent U.S. tariff measures on pharmaceutical imports have resulted in rising production costs for targeted therapies and checkpoint inhibitors, prompting manufacturers to diversify supply chains and reevaluate regional sourcing. This disruption extends to clinical trial operations, where sponsors are adopting advanced warehousing and dual-source strategies to minimize delays and protect patient access, especially during key trial enrollment and site activation periods.

Research Methodology & Data Sources

Analysis draws on primary insights from oncologists, trial investigators, and pharmaceutical executives, complemented by review of regulatory filings, healthcare databases, and published clinical evidence. Secondary intelligence from payer and health technology agencies enriches understanding of reimbursement frameworks and market access dynamics.

Why This Report Matters

  • Delivers actionable intelligence for developing resilient commercial and supply chain strategies in the face of shifting regulatory and economic policies.
  • Enables market leaders to tailor development and deployment of therapies, ensuring alignment with evolving payer requirements and diverse regional market forces.

Conclusion

This report equips decision-makers to anticipate and address the complexities of the unresectable hepatocellular carcinoma market with evidence-driven insights and strategic clarity. Leaders will be positioned to capitalize on evolving opportunities while effectively managing risk.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of CDK4/6 inhibitors combined with immune checkpoint therapy improving response rates in advanced unresectable hepatocellular carcinoma
5.2. Adoption of liquid biopsy assays for early detection and monitoring of treatment resistance in unresectable hepatocellular carcinoma
5.3. Expansion of second-line multikinase inhibitors following progression on first-line immunotherapy in uHCC patients
5.4. Integration of AI-powered imaging analytics to predict tumor vascularization and guide locoregional therapies in unresectable hepatocellular carcinoma
5.5. Uptake of dual VEGF and PD-1 blockade regimens to overcome immunotherapy resistance in advanced unresectable hepatocellular carcinoma
5.6. Emerging role of gut microbiome modulation in enhancing checkpoint inhibitor efficacy in unresectable hepatocellular carcinoma
5.7. Development of bispecific antibodies targeting GPC3 and PD-L1 to improve survival outcomes in unresectable hepatocellular carcinoma patients
5.8. Exploration of personalized neoantigen vaccines to stimulate tumor-specific T cell responses in advanced unresectable HCC patients
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Unresectable Hepatocellular Carcinoma Market, by Therapy Type
8.1. Introduction
8.2. Combination Therapy
8.3. Locoregional Therapy
8.4. Supportive Care
8.5. Systemic Therapy
9. Unresectable Hepatocellular Carcinoma Market, by Mechanism Of Action
9.1. Introduction
9.2. Immune Checkpoint Inhibitors
9.2.1. Ctla-4 Inhibitors
9.2.2. Pd-1 Inhibitors
9.2.3. Pd-L1 Inhibitors
9.3. Mtor Inhibitors
9.4. Tyrosine Kinase Inhibitors
9.4.1. Multi Kinase Inhibitors
9.4.2. Selective Kinase Inhibitors
10. Unresectable Hepatocellular Carcinoma Market, by Line Of Therapy
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line
11. Unresectable Hepatocellular Carcinoma Market, by Formulation
11.1. Introduction
11.2. Injectable
11.3. Oral
12. Unresectable Hepatocellular Carcinoma Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Unresectable Hepatocellular Carcinoma Market, by End User
13.1. Introduction
13.2. Home Care Settings
13.3. Hospitals
13.4. Specialty Clinics
14. Americas Unresectable Hepatocellular Carcinoma Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Unresectable Hepatocellular Carcinoma Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Unresectable Hepatocellular Carcinoma Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. F. Hoffmann-La Roche Ltd
17.3.2. Genentech, Inc.
17.3.3. Eisai Co., Ltd.
17.3.4. Bayer AG
17.3.5. Merck & Co., Inc.
17.3.6. Bristol-Myers Squibb Company
17.3.7. Exelixis, Inc.
17.3.8. Eli Lilly and Company
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET: RESEARCHAI
FIGURE 28. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET: RESEARCHSTATISTICS
FIGURE 29. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET: RESEARCHCONTACTS
FIGURE 30. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MULTI KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MULTI KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SELECTIVE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SELECTIVE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 107. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 108. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 109. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 110. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 111. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 112. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 113. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 114. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 115. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 116. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 117. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 118. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 119. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 124. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 125. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 126. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 127. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 128. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 129. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 130. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 131. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 132. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 133. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 134. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 135. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 206. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 207. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 208. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 209. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 210. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 211. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 212. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 213. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 214. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 215. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 216. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 217. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 222. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 223. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 224. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 225. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 226. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 227. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 228. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 229. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 230. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 231. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 232. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 233. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 254. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 255. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 256. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 257. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 258. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 259. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 260. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 261. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 262. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 263. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 264. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 265. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 270. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 271. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 272. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 273. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 274. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 275. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 276. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 277. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA M

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Unresectable Hepatocellular Carcinoma market report include:
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Eisai Co., Ltd.
  • Bayer AG
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Exelixis, Inc.
  • Eli Lilly and Company

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.16 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.05 Billion
Compound Annual Growth Rate13.4%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Unresectable Hepatocellular Carcinoma - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Unresectable Hepatocellular Carcinoma - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 129 Pages
  • Global
From
Unresectable Hepatocellular Carcinoma Market Report 2025 - Product Image

Unresectable Hepatocellular Carcinoma Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Metastatic Hepatocellular Carcinoma- Pipeline Insight, 2025 - Product Image

Metastatic Hepatocellular Carcinoma- Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Hepatocellular Carcinoma Epidemiology Forecast 2025-2034 - Product Image

Hepatocellular Carcinoma Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From
Hepatocellular Carcinoma Drugs - Global Strategic Business Report - Product Image

Hepatocellular Carcinoma Drugs - Global Strategic Business Report

  • Report
  • 198 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.